- Home
- HOOD vs SNY Comparison
HOOD vs SNY Comparison
Compare HOOD & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HOOD | SNY |
|---|---|---|
| Founded | 2013 | 1994 |
| Country | United States | France |
| Employees | N/A | 74846 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.9B | 116.8B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | HOOD | SNY |
|---|---|---|
| Price | $76.88 | $44.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 6 |
| Target Price | ★ $111.62 | $61.50 |
| AVG Volume (30 Days) | ★ 21.0M | 3.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.60% |
| EPS Growth | ★ 31.41 | N/A |
| EPS | ★ 2.05 | N/A |
| Revenue | ★ $4,473,000,000.00 | N/A |
| Revenue This Year | $26.65 | $3.01 |
| Revenue Next Year | $17.79 | $5.80 |
| P/E Ratio | $37.58 | ★ $6.14 |
| Revenue Growth | ★ 51.58 | N/A |
| 52 Week Low | $29.66 | $43.49 |
| 52 Week High | $153.83 | $59.13 |
Technical Indicators
Market Signals| Indicator | HOOD | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 44.51 | 39.72 |
| Support Level | $69.83 | N/A |
| Resistance Level | $77.80 | $48.97 |
| Average True Range (ATR) | 3.56 | 0.66 |
| MACD | 0.89 | -0.20 |
| Stochastic Oscillator | 38.32 | 19.01 |
Price Performance
Historical ComparisonAbout HOOD Robinhood Markets Inc.
Robinhood Markets Inc is creating a modern financial services platform. It designs its own products and services and delivers them through a single, app-based cloud platform supported by proprietary technology. Its vertically integrated platform has enabled the introduction of new products and services such as cryptocurrency trading, dividend reinvestment, fraud detection, derivatives, fractional shares, recurring investments, and others.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.